NYU Langone doctors are committed to conducting clinical research for the benefit of people who have neurofibromatosis. Clinical trials are research studies that aim to identify new and promising approaches to treatment and to gain regulatory approval for them through the U.S. Food and Drug Administration.
Researchers at NYU Langone were some of the first to successfully complete clinical trials investigating new drugs, such as lapatinib and everolimus, to improve hearing and reduce tumor size in people with neurofibromatosis type 2. Our researchers also collaborate with investigators at other institutions to conduct clinical trials.
In 2011, NYU Langone’s Comprehensive Neurofibromatosis Center was granted membership in the Neurofibromatosis Clinical Trials Consortium, or NFCTC, supported by the U.S. Department of Defense. The goal of the NFCTC is to conduct clinical trials for serious complications of all types of neurofibromatosis.
Currently, NFCTC-sponsored clinical trials available at NYU Langone involve new approaches to treating people with neurofibromatosis type 1 with associated learning disabilities, pseudarthrosis of the tibia, which is the large bone located in the lower leg, cancerous peripheral nerve sheath tumors, and plexiform neurofibromas that are growing and causing symptoms.
There are also trials for people who have neurofibromatosis type 2 with symptomatic vestibular schwannomas. As the only participating neurofibromatosis center in the New York tri-state region, we are pleased to offer such important and promising new treatments for people with neurofibromatosis.
Find a list of all of NYU Langone’s currently open clinical trials for people who have neurofibromatosis.
Learn more about our research and professional education opportunities.